Check for updates

Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas

Sophie Katzendobler[1], Anna Do[1], Jonathan Weller[1], Mario M. Dorostkar[2],
Nathalie L. Albert[3,4], Robert Forbrig[5], Maximilian Niyazi[4,6], Rupert Egensperger[2],
Niklas Thon[1], Joerg Christian Tonn[1,4] and Stefanie Quach[1]*

[1] Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany, [2] Center for Neuropathology and Prion Research, LMU Munich, Munich, Germany, [3] Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany, [4] German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany, [5] Institute of Neuroradiology, University Hospital, LMU Munich, Munich, Germany, [6] Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

Background: An integrated diagnosis consisting of histology and molecular markers is the basis of the current WHO classification system of gliomas. In patients with suspected newly diagnosed or recurrent glioma, stereotactic biopsy is an alternative in cases in which microsurgical resection is deemed to not be safely feasible or indicated. In this retrospective study, we aimed to analyze both the diagnostic yield and the safety of a standardized biopsy technique.

Material and Methods: The institutional database was screened for frame-based biopsy procedures (January 2016 until March 2021). Only patients with a suspected diagnosis of glioma based on imaging were included. All tumors were classified according to the current WHO grading system. The clinical parameters, procedural complications, histology, and molecular signature of the tissues obtained were assessed.

Results: Between January 2016 and March 2021, 1,214 patients underwent a stereotactic biopsy: 617 (50.8%) for a newly diagnosed lesion and 597 (49.2%) for a suspected recurrence. The median age was 56.9 years (range 5 months−94.4 years). Magnetic resonance imaging (MRI)-guidance was used in 99.3% of cases and additional positron emission tomography (PET)-guidance in 34.3% of cases. In total, stereotactic serial biopsy provided an integrated diagnosis in 96.3% of all procedures. The most frequent diagnoses were isocitrate dehydrogenase (IDH) wildtype glioblastoma ($n = 596$; 49.2%), oligodendroglioma grade 2 ($n = 109$; 9%), astrocytoma grade 3 ($n = 108$; 8.9%), oligodendroglioma grade 3 ($n = 76$; 6.3%), and astrocytoma grade 2 ($n = 66$; 5.4%). A detailed determination was successful for IDH 1/2 mutation in 99.4% of cases, for 1p/19q codeletion in 97.4% of cases, for TERT mutation in 98.9% of cases, and for *MGMT* promoter methylation in 99.1% of cases. Next-generation sequencing was evaluable in 64/67 (95.5%) of cases and DNA methylome analysis in 41/44 (93.2%) of cases. Thirteen (1.1%) cases showed glial tumors that could not be further specified. Seventy-three tumors were different non-glioma entities, e.g., of infectious or inflammatory nature. Seventy-five out of 597 suspected recurrences turned out to be post-therapeutic changes only. The rate of

post-procedural complications with clinical symptoms of the Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher was 1.2% in overall patients and 2.6% in the subgroup of brainstem biopsies. There was no fatal outcome in the entire series.

Conclusion: Image-guided stereotactic serial biopsy enables obtaining reliable histopathological and molecular diagnoses with a very low complication rate even in tumors with critical localization. Thus, in patients not undergoing microsurgical resection, this is a valuable tool for precision medicine of patients with glioma.

INTRODUCTION

Gliomas represent a heterogeneous group of neoplasms of the central nervous system. Classification and subsequent management decisions depend on histological and molecular features. The WHO provides the framework for classification which leads to the guidelines for clinical management (1–5).

Hence, both histology and molecular diagnosis are mandatory in newly diagnosed intracerebral lesions suspicious for glioma. This can be obtained either by tumor resection or stereotactic biopsy. Whether the patient should undergo an open, microsurgical tumor resection or just a biopsy depends mainly on the clinical status of the patient, location and extent of the lesion, and the patients' preference. Gross total resection is associated with better long-term outcome but also inherits a risk of perioperative and postoperative complications despite modern neurosurgical techniques (6–8). Conversely, biopsies are not used for the reduction of tumor volume and but are administered for tissue-based diagnosis only (9). They can be minimally invasive, provide both histological and molecular diagnosis, and may be more suitable for multimorbid or frail patients with very high surgical risk factors for midline tumors or patients with gliomas in highly eloquent areas of the brain bearing a high functional risk in case of extensive tumor reduction.

Especially in *MGMT* methylated glioblastomas, and also in IDH mutated gliomas, treatment-induced changes on conventional magnetic resonance imaging (MRI) are not always easily distinguishable from true tumor progression, a phenomenon termed pseudoprogression (10, 11). Despite the added value of advanced MRI including MR perfusion and MR spectroscopy and positron emission tomography (PET) using radiolabeled amino acids (e.g., O-(2-[18]Ffluorethyl)-L-tyrosine ([^{18}F]FET PET)) to assess the real tumor burden (12–14), tissue sampling provides the gold standard of information for further management of these uncertain cases.

Tumor relapse is not only a hallmark of IDH wild type glioblastoma but also occurs frequently in lower grade, IDH mutant gliomas (15–17). Patients, thus, are often subjected to a multitude of therapies over time given the fact that, so far, no standard treatment for recurrent gliomas exists. Individualized, targeted therapy is an emerging field in the treatment of gliomas and tissue sampling is necessary to identify the druggable targets using next-generation sequencing. Drugs directed against receptor tyrosine kinases (RTK) and downstream molecules like PI3K/AKT/mTOR as well as drugs targeting the mitogen-activated protein kinase (MAPK) signaling pathway are currently under investigation (2, 18, 19). Small-molecule inhibitors targeting IDH mutations are being tested in clinical trials (NCT02073994, NCT02481154). As mutational landscapes of gliomas may change during therapy and disease course, a safe and efficient way to obtain glioma tissue for identification of targetable molecular alterations would be of great benefit (20).

Thus, there is a growing need to obtain a tissue-based diagnosis even at multiple points in time during the clinical course of glioma. A minimally invasive approach would be desirable to accomplish the goal of having maximally informative specimens with minimal risk and burden for the patient. Whether risks and gains of stereotactic biopsies are well-balanced has been a matter of debate for a long time (21). However, the diagnostic yield in the framework of a molecular-driven brain tumor diagnosis and the associated complication rates of biopsies initially and during clinical course have not yet been investigated comprehensively. In this retrospective study, we aimed at analyzing both the diagnostic yield and the safety of a standardized biopsy technique between 2016 and 2021 in a single high-volume center with a high number of tertiary referrals.

MATERIALS AND METHODS

Patient Evaluation

The local database of the Department of Neurosurgery of the University Hospital Munich (Ludwig-Maximilians University) was screened for all biopsy procedures in a 5-year period between January 2016 and March 2021. Only patients with a suspected diagnosis of glioma were included. After histological confirmation of a glioma through biopsy, molecular analyses were performed. Clinical parameters such as age at diagnosis, Karnofsky Performance Status (KPS), initial symptoms, date of stereotactic biopsy, postoperative clinical course, and last follow-up were assessed retrospectively. All patients or caregivers gave written informed consent. The local ethics committee of the University Hospital Munich approved the study (project number 325-2011).

FIGURE 1 | Biopsy trajectory planning **(A)**, sample size of acquired specimen [arrows, **(B,C)**], and skin incision **(D)**.

Biopsy Technique

A standardized frame-based imaging-guided stereotactic biopsy technique was used in all patients. The preoperative workup comprised a 1.5 or 3T MRI scan (with T2 and T1 sequences before and after application of a Gadolinium-based contrast agent and MR-angiography sequences) that was acquired 1 day prior to surgery and fused with an intraoperative, contrast-enhanced CT angiography scan (**Figure 1**). If available, the PET imaging data based on [18F]FET PET was included in the triplanar trajectory planning (**Figure 2**). Each trajectory was meticulously planned to avoid any risk of vascular damage, contact to sulci, or drainage of the cerebrospinal fluid (CSF), which may lead to an intraoperative brain shift with a subsequent mismatch between planning MRI and real anatomy. A phantom frame was used to confirm the correct 3-dimensional angulation prior to the surgery in all patients. If present, the T1 contrast-enhancing lesions and/or suspicious [18F]FET PET foci were targeted. After attaching the frame under sterile conditions, a skin incision of 4–6 mm is made and followed by a frame-guided burr hole trepanation with a diameter of 3 mm. After perforation of the dura through advancing a sharp trocar, a blunt trocar inside a guiding tube (1.4 mm guide tube and trocar, Medical High Tech GmbH, Bad-Krozingen-Biengen, Germany) is used to reach the lesion. Subsequently, with the guide tube in place, multiple small tissue samples of 1 mm^3 each are taken by utilizing the designated biopsy forceps (Medical High Tech GmbH,

Bad-Krozingen-Biengen, Germany) inserted into the guide tube. Usually, 5–30 individual specimens per trajectory were taken depending on tumor size and the relation between solid tumor and necrosis. Thereafter, the skin is closed with a single stitch. The average length of the procedure, including the intraoperative CT scan, is 50.4 min.

An experienced neuropathologist is on site in the OR during the procedure to check *via* smear preparation whether the material obtained is sufficient in terms of quantity and quality for diagnosis.

Complications and Follow-Up

Complications were classified according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0; **Supplementary Table 1**) (22). Complications receding within 3 months were classified as transient, else they were classified as permanent. The routine follow-up after biopsy consisted of a postoperative CT scan on the first day after the procedure and an MRI follow-up in 3–6 months intervals for high-grade gliomas and low-grade gliomas, respectively.

Histology and Molecular Markers

All glioma specimens were classified according to the WHO 2016 at the Center for Neuropathology and Prion Research of the University Hospital Munich and retrospectively re-classified according to the WHO 2021 (3). Routine molecular analysis at

FIGURE 2 | Example of a multimodal trajectory planning targeting both contrast- and (fluorethyl)-L-tyrosine (FET)-enhancing areas in a case of a suspected recurrence of a multimodally treated oligodendroglioma, IDH mutated and 1p/19q co-deleted, the central nervous system (CNS) WHO grade 3. **(Upper panel)** Axial view of contrast enhanced T1, CT, FET positron emission tomography (PET), and T2. **(Lower panel)** Inline view depicting the trajectory plane.

first diagnosis comprised immunohistochemical staining against R132H-mutated IDH1 and ATRX and PCR-based analysis of the IDH1 and 2 mutational hotspots, R312 and R172, respectively (PyroMark Q24 System, Pyro Gold reagents kit, Qiagen, Hilden, Germany); a microsatellite marker analysis was used for the detection of 1p and 19q deletions (23, 24). The mutations within the TERT promoter sequence were detected by the Sanger sequencing utilizing the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany), the BigDye Terminator V3.1 Cycle Sequencing kit (Life Technologies, Carlsbad, USA), the DyeEX 2.0 Spin Kit (Qiagen, Hilden, Germany), and 3130 Genetic Analyzer (Life Technologies, Carlsbad, USA) (25). The DNA methylation status of the *MGMT* promoter was determined by bisulfite modification and subsequent nested methylation-specific PCR and sequencing analysis. Tumors were classified binarily as methylated or unmethylated (26). Further molecular analyses were initiated when the results were inconclusive or when aiming at identifying targetable mutations in patients with conventional treatment failure. In these cases, next-generation sequencing was performed using a combined DNA and RNA panel (Trusight Oncology 500, Illumina, San Diego, CA, USA). The DNA methylation profiling was performed for tumor not classifiable by other means or to detect clinically or diagnostically relevant copy number alterations such as homozygous CDNK2A/B deletions. The methylation profiling was done using an Illumina Infinium MethylationEPIC BeadChip array (Illumina, San Diego, CA, USA) with subsequent data analysis using the DNA methylation-based brain tumor classifier provided by the Deutsche Krebsforschungszentrum (v11b4) (27).

Statistics

The final database contained patient-related, clinical, and tumor-specific information such as patient age at diagnosis, gender, clinical status utilizing the KPS, localization of the tumor, histological and molecular glioma features, and postinterventional complication rates. Based on this data, descriptive statistical analyses were performed utilizing the SPSS Statistics 25 software (IBM, Armonk, New York, USA).

RESULTS

Patients and Procedural and Tumor Characteristics

In total, 1,214 consecutive biopsy procedures were analyzed. The median age of patients was 56.9 years (range 5 months−94.4 years). Of the total patients, 58.6% were men and 41.4% were women. A KPS of 80 or higher was reported in 82.1% of all patients. In 50.8% of cases, a biopsy was performed to obtain tissue in a newly diagnosed tumor and in 49.2% of cases for suspected recurrence. Image guidance was based on MRI in 99.3% cases and on CT in 0.7% cases due to contraindications for MRI imaging. Additionally, [^{18}F]FET PET was used in 34.3% cases.

A total of 596 tumors (49.1%) were located on the left and 535 (44.1%) on the right side, and 83 patients (6.8%) had a bilateral midline tumor. The tumor site was lobar in 1,011 (83.3%), deep seated (insula, thalamus, corpus callosum, pineal region) in 123 (10.1%), cerebellar in 40 (3.3%), and

TABLE 1 | Biopsy location in primary and recurrent diseases.

Location		First diagnosis n (%)	Recurrence n (%)	Total n (%)
Lobar	Frontal	155 (12.8)	232 (18.4)	378 (31.1)
	Temporal	158 (13.0)	161 (13.3)	319 (26.3)
	Parietal	79 (6.5)	78 (6.4)	157 (12.9)
	Occipital	15 (1.2)	12 (1.0)	27 (2.2)
	Pre-/postcentral gyrus	67 (5.5)	63 (5.2)	130 (10.7)
Deep-seated	Callosal	12 (1.0)	3 (0.2)	15 (1.2)
	Insular	27 (2.2)	26 (2.1)	53 (4.4)
	Thalamic	31 (2.6)	6 (0.5)	37 (3.0)
	Pineal	15 (1.2)	3 (0.2)	18 (1.5)
	Cerebellar	25 (2.1)	15 (1.2)	40 (3.3)
Brainstem	Mesencephalon	8 (0.7)	3 (0.2)	11 (0.9)
	Pons	14 (1.2)	4 (0.3)	18 (1.5)
	Medulla oblongata	11 (0.9)	0 (0.0)	11 (0.9)
Total		617 (50.8)	597 (49.2)	1,214 (100.0)

brainstem in 40 (3.3%) patients (for detailed location see **Table 1**).

The most common diagnosis was glioblastoma IDH wild type with 596 cases (49.2%), followed by oligodendroglioma grade 2 ($n = 109$; 9.2%), astrocytoma grade 3 ($n = 108$; 8.9%), oligodendroglioma grade 3 ($n = 76$; 6.4%), astrocytoma grade 2 ($n = 66$; 5.4%), IDH 1/2 mutated astrocytoma WHO grade 4 ($n = 45$; 3.7%), and diffuse midline glioma, H3K27M- or FGFR1-mutated ($n = 15+1$; 1.3%) (**Table 2**).

Diagnostic Yield and Molecular Analyses

Among all newly diagnosed lesions, histopathology and molecular analyses provided a definite diagnosis in 595/617 cases (96.4%). Among the 22 unclear results, 14 patients were followed up by MRI imaging, as a low-grade tumor in an eloquent location was histologically and clinically the most likely diagnosis. None of these patients experienced tumor progression during a mean follow-up of 21 months. In six cases, the treatment was initiated based on recommendations by our interdisciplinary tumor board according to the most likely diagnosis (3 glial tumors without further subclassification; 3 diagnoses other than glioma). In only two cases, a second invasive procedure was required for obtaining the diagnosis: one patient underwent re-biopsy after 2 weeks, confirming IDH wild type glioblastoma, and another patient underwent open tumor resection revealing ganglioglioma.

Among all suspected recurrences, vital tumor was detected in 522 out of 597 cases (87.1%), while predominantly post-therapeutic changes were found in 75 cases (12.6%). In 3 cases (4% of all tissues showing post-therapeutic changes), recurrence within 3 months suggested a false negative sampling. In three cases with histologically diagnosed tumor recurrence (0.6%), further clinical course suggested mainly post-therapeutic changes, i.e., false-positive sampling. This amounts to a positive predictive value of 99.4% and a negative predictive value of 96%.

The standard molecular analyses, required by the WHO 2021 grading system, were successfully obtained in the vast majority of

tumors being identified as gliomas by histology. The molecular status was informative for IDH 1/2 mutation in 99.4%, for 1p/19q codeletion in 97.4%, for TERT mutation in 98.9%, and for *MGMT* promoter methylation in 99.1%. Next-generation sequencing was attempted in 67 cases and evaluable in 64. The DNA methylation analysis was attempted in 44 cases and evaluable in 42. Twelve, thereof, showed no match with known methylation classes. Altogether, a successful molecular characterization for integrated diagnosis was obtained in 93% of all newly diagnosed and in 88.3% of all recurrent lesions.

Complications

The routine postoperative CT showed no visible conspicuity in 816 (67.2%) cases, a minimal (<5 mm) hemorrhage in 305 (25.1%) cases, a local (>5 mm) hemorrhage in 51 (4.2%) cases, and a space-occupying hemorrhage in 10 (0.8%) cases. In 30 cases, no postoperative CT scan was performed in young patients without relevant deficit. **Table 3** lists clinical complications in relation to imaging features. No clinical sequelae of the stereotactic biopsy were observed in 1,164 (95.9%) of procedures. Mild complications (CTCAE grade 1) were documented in 14 (1.2%) and moderate (CTCAE° 2) in 21 (1.7%) cases. Complications of CTCAE grade 3 occurred in 11 procedures (5 hemiparesis, 4 seizure series, 3 cases of delirium, 1 reduced level of consciousness, total 0.9%). Four patients (0.3%) required urgent intervention (CTCAE grade 4): three patients with postoperative bleeding required craniotomy and hematoma evacuation. One of these patients re-bled a second time after an initially successful hematoma evacuation and needed a second revision craniotomy, possibly due to a decreased level of fibrin stabilizing factor (factor XIII) diagnosed after the second revision surgery. All three patients with hematoma evacuation improved to CTCAE grade 1 or 0 within 3 months. One superficial wound infection required local debridement. Regarding the subgroup of brainstem lesions, two patients (5.3%) experienced mild complications and one (2.6%) a moderate complication (local hemorrhage with transient aggravation of a preexisting

TABLE 2 | Histological diagnoses.

Entity		Newly diagnosed lesion n (%)	Recurrence n (%)	Total n (%)
Glioma	Glioblastoma, IDH wild type	354 (29.2)	243 (20.1)	596 (49.2)
	Midline glioma, H3K27M-mutated	12 (1.0)	3 (0.2)	15 (1.2)
	Astrocytoma WHO grade 4, IDH-mutant	4 (0.3)	41 (3.4)	45 (3.7)
	Astrocytoma WHO grade 3, IDH-mutant	19 (1.6)	89 (7.3)	108 (8.9)
	Astrocytoma WHO grade 2, IDH-mutant	34 (2.8)	32 (2.6)	66 (5.4)
	High-grade astrocytoma with piloid features	3 (0.2)	1 (0.1)	4 (0.3)
	Oligodendroglioma WHO grade 3, IDH-mutant and 1p/19q-codeleted	8 (0.7)	68 (5.6)	76 (6.3)
	Oligodendroglioma WHO grade 2, IDH-mutant and 1p/19q-codeleted	37 (3.0)	72 (5.9)	109 (9.0)
	Ganglioglioma	7 (0.6)	4 (0.3)	11 (0.9)
	Pilocytic astrocytoma	11 (0.9)	13 (1.1)	24 (2.0)
	Pleiomorphic xanthoastrocytoma	0 (0.0)	1 (0.1)	1 (0.1)
	Pleiomorphic astroglial tumor	2 (0.2)	0 (0.0)	2 (0.2)
	Ependymoma	1 (0.1)	1 (0.1)	2 (0.2)
	Anaplastic ependymoma	2 (0.2)	3 (0.2)	5 (0.4)
Other gliomas, not elsewhere classified (NEC)	Glioma (NEC)	1 (0.1)	0 (0.0)	1 (0.1)
	Glial tumor	11 (0.9)	1 (0.1)	12 (1.0)
	Glioneural tumor	7 (0.6)	0 (0.0)	7 (0.6)
	Neuroepithelial tumor	7 (0.6)	1 (0.1)	8 (0.7)
Other	Initially suspected glioma, diagnosis other than glioma	41 (3.4)	4 (0.3)	45 (3.7)
	Metastasis	31 (2.6)	2 (0.2)	33 (2.7)
	Medulloblastoma	3 (0.2)	4 (0.3)	7 (0.6)
	Meningioma	6 (0.5)	4 (0.3)	10 (0.8)
	Neurocytoma	3 (0.2)	2 (0.2)	5 (0.4)
	Germinoma	6 (0.5)	1 (0.1)	7 (0.6)
	Other entities (pineocytoma, neurinoma, diffuse leptomeningeal glioneuronal tumor, papillary tumor of the pineal region, pineoblastoma, solitary fibrous tumor, craniopharyngioma, yolk sac tumor)	7 (0.7)	7 (0.7)	14 (1.3)
Total		617 (50.8)	597 (49.2)	1,214 (100.0)

hemiparesis). In total, 74% of all clinical complications were resolved within 3 months (**Table 4**). There were no procedure-related deaths in the overall cohort.

Brainstem Biopsies

A subgroup of 40 patients underwent a stereotactic biopsy of a brainstem lesion, whereof 13 were pediatric patients. The most frequent diagnosis was diffuse midline glioma, H3K27M mutated ($n = 8$), glioblastoma IDH wild type ($n = 5$), IDH 1/2 mutated astrocytoma ($n = 7$), and pilocytic astrocytoma ($n = 5$). All diagnoses of brainstem tumors are detailed in **Table 5**. In six cases, another diagnosis other than tumor was made, which was confirmed also by a further clinical course. NGS and DNA methylation analysis was attempted and successfully performed in three cases each. Two patients (5.3%) experienced mild complication and one (2.6%) patient had a moderate complication (local hemorrhage which transient aggravation of a preexisting hemiparesis).

DISCUSSION

With the help of image-guided stereotactic biopsy, we could establish a histopathological and molecular diagnosis and distinguish true progression from pseudoprogression in a consecutive series of 1,214 patients with suspected glioma with a very high diagnostic accuracy of 96.4% in terms of histology, over 97% for molecular markers, and over 95% in 850 k/NGS arrays. The rate of non-gliomas among all suspected gliomas was low, possibly reflecting that an interdisciplinary tumor board with dedicated experienced neuroradiologists and nuclear medicine physicians had put forward the biopsy indications. Most previously published studies comprised sample sizes of a few dozen to a couple hundred patients (28–36). The largest retrospective monocentric study comprised 622 patients biopsied over the course of 20 years as compared to a sample size of 1,214 patients over 5 years reported in our study (28, 30). The rate of biopsies investigating

TABLE 3 | Complications according to postoperative imaging and severity.

Blood on postoperative CT scan (*n*, % of total)	Clinical complications (CTCAE grade)	Newly diagnosed lesions; *n* (%)	Recurrent lesions; *n* (%)	Total; *n* (%)
No visible blood (*n* = 816; 67.2%)	0 (none)	395 (98.0)	406 (98.3)	801 (98.2)
	1 (mild)	2 (0.5)	3 (0.7)	5 (0.6)
	2 (moderate)	6 (1.5)	2 (0.5)	8 (1.0)
	3 (severe)	0	2 (0.5)	2 (0.2)
Minimal (<5 mm) hemorrhage (*n* = 305; 25.1%)	0 (none)	149 (96.1)	142 (94.7)	291 (95.4)
	1 (mild)	0	4 (2.7)	4 (1.3)
	2 (moderate)	5 (3.2)	4 (2.7)	9 (3.0)
	3 (severe)	1 (0.6)	0	1 (0.3)
Local (>5 mm) Hemorrhage (*n* = 51; 4.2%)	0 (none)	26 (81.3)	16 (84.2)	42 (82.4)
	1 (mild)	2 (6.3)	1	3 (5.9)
	2 (moderate)	1 (3.1)	1 (5.3)	2 (3.9)
	3 (severe)	2 (6.3)	1 (5.3)	3 (5.9)
	4 (life-threatening)	1 (3.1)	0	1 (2.0)
Space occupying hemorrhage (*n* = 10; 0.8%)	2 (moderate)	1 (16.7)	1 (25.0)	2 (20.0)
	3 (severe)	2 (33.3)	3 (75.0)	5 (50.0)
	4 (life-threatening)	3 (50.0)	0	3 (30.0)
Ischemia (*n* = 2; 0.8%)	0 (none)	0	1 (50.0)	1 (50.0)
	1 (mild)	0	1 (50.0)	1 (50.0)
No imaging available (*n* = 30; 2.5%)	0 (none)	20 (95.2)	9 (100)	29 (96.7)
	1 (mild)	1 (4.8)	0	1 (3.3)
Total (*n* = 1,214; 100%)	0 (none)	590 (95.6)	574 (96.1)	1,164 (95.9)
	1 (mild)	5 (0.8)	9 (1.5)	14 (1.2)
	2 (moderate)	13 (2.1)	8 (1.3)	21 (1.7)
	3 (severe)	5 (0.8)	6 (1.0)	11 (0.9)
	4 (life-threatening)	4 (0.6)	0	4 (0.3)

TABLE 4 | Fraction of transient or permanent complications among all complications.

Clinical complications (CTCAE grade)	Transient *n* (% of total)	Permanent *n* (% of total)	Total *n* (% total)
1	12 (0.9)	2 (0.2)	14 (1.2)[a]
2	17 (1.4)	4 (0.3)	21 (1.7)
3	4 (0.3)	7 (0.6)	11 (0.9)
4	4 (0.3)	0 (0.0)	4 (0.3)
Total	37 (3.0)	13 (1.1)	50 (4.1)

[a]*Percentages do not add up due to rounding.*

TABLE 5 | Diagnoses of brainstem biopsies in adult and pediatric patients.

	Adult *n* (%)	Pediatric *n* (%)	Total *n* (%)
Midline glioma	3 (11.1)	5 (38.5)	8 (20.0)
Glioblastoma, IDH wildtype	3 (11.1)	2 (15.4)	5 (12.5)
Astrocytoma, IDH mutated	6 (22.2)	1 (7.7)	7 (17.5)
Astrocytoma with piloid features	1 (3.7)	0 (0.0)	1 (2.5)
Oligodendroglioma, IDH mutated, 1p/19q codeleted	1 (3.7)	0 (0.0)	1 (2.5)
Pilocytic astrocytoma	3 (11.1)	2 (15.4)	5 (12.5)
Glial tumor, NEC	3 (11.1)	0 (0.0)	3 (7.5)
Glioneuronal tumor	1 (3.7)	0 (0.0)	1 (2.5)
Papillary tumor of the pineal region	0 (0.0)	1 (7.7)	1 (2.5)
Metastasis	2 (7.4)	0 (0.0)	2 (5.0)
Other diagnoses than tumor	4 (14.8)	2 (15.4)	6 (15.0)
Total	27 (100)	13 (100)	40 (100)

suspected tumor recurrence is relatively high, as we provide an effective, low-risk stereotactic biopsy technique and have many patients with suspected recurrences coming to our tertiary referral center for second opinions and to get a tissue-based diagnosis, which is decisive to maintain a successful therapy or enable an informed change of therapy. Unspecific therapy-related changes and pseudoprogression phenomena mimicking tumor relapse gain more importance in light of emerging immunotherapies (37). In our series, more than one in ten (12.5%) of suspected tumor recurrences showed only therapy-induced changes histologically, obviating the need for more invasive procedures in this patient collective. In addition, in analogy to solid cancers and brain metastases, the search for druggable targets in newly diagnosed and recurrent gliomas just embarks and will increase in the future. As new therapies being recommended by a molecular tumor board become available, tissue diagnosis of possible druggable targets should not be withheld from "biopsy-only" patients. Consequently, in all cases where open microsurgical resection is not deemed feasible or medically justified and in all "diagnostic-only" situations, the need for a minimal invasive and maximal effective technique to obtain an informative diagnostic material is beyond doubt. This has also been adopted now for diffuse brainstem gliomas (38, 39).

Earlier, small biopsies did not yield enough viable tissue for obtaining a valid and, presently, mandatory molecular diagnosis; however, the contemporary refined technologies of molecular biology enable the analysis of a panel of different molecular markers even from very small specimens (40, 41). Only with access to elaborate the neuropathological technique and expertise, stereotactic biopsies are adequate to gain all diagnostic information in case open resection is not deemed feasible or justified. In our series, over 96% of biopsies were informative concerning histology and the molecular signature of the tumor. Prerequisite for a proper molecular diagnosis is to obtain the material out of the solid parts of the tumor since any "contamination" of the specimen with either normal adjacent brain or else tumor necrosis might hamper diagnostic yield and accuracy. Moreover, the neuropathologist has to be experienced in working up these small samples. In our practice, the pathologist is on site in the OR during the procedure to check *via* smear preparation whether the material obtained is sufficient in terms of quantity and quality for diagnosis.

Serial sampling with multiple specimens along the trajectory allows to "map" the tumor, including its infiltration zone. This is extremely useful in heterogeneously composed tumors where one single biopsy might lead to a sampling error like misdiagnosing or undiagnosed. MR features such as contrast enhancement on T1-weighted imaging or cell density on T2-weighted sequences can highlight the suspicious areas that should be targeted preferentially. PET with amino acid tracers such as [18F]FET, [11C]Methionine, or [18F]FDOPA are particularly useful to detect the relevant areas for diagnostic biopsies in either diffuse, non-contrast enhancing gliomas or in multimodally pretreated lesions with differential diagnosis of recurrent tumor vs. treatment-related phenomena (12, 13, 42, 43). While [18F]FET PET and perfusion MRI can give important hints about the likelihood of true progression vs. pseudoprogression (12), our

data support the continued use of histology as the gold standard for identifying both with high reliability and low risk. Furthermore, image-guided biopsies allow to precisely target and sample different areas within heterogeneously composed tumors to address the mutational and clonal analyses with a high spatial resolution.

As long as molecular alterations within the tumor are homogeneously distributed, sampling errors are not an issue. Referring to this, the homogeneous distribution of the alteration has to be shown in a systemical order to elucidate whether a risk of sampling error might be relevant for a given particular marker. This has been demonstrated for most of the relevant basic molecular signatures in gliomas (26, 43, 44). The earlier a molecular alteration appears in the timeline of tumor evolution, the more likely it can appear homogeneously within the tissue (45). Conversely, especially for late events, more heterogeneous patterns evolve, which have to be taken into account for biopsy (46).

The patterns of either diagnostic or therapeutic targets may change during the course of disease, so recurrent tumors may have a completely different pattern compared to the original newly diagnosed tumor. Again, early events in the tumorigenesis may not change, whereas new subclones during tumor progression may carry new mutations (45). Especially, therapy-driven alterations and an increase in mutational burden may necessitate re-biopsy (47–50). Whereas, *MGMT* promoter methylation does not change over time (51), other therapy relevant markers do (52, 53). Hence, it may not justified to include patients with recurrent tumors into clinical trials for targeted therapy just on the basis of the initial specimen. Instead, dependent on the target, the molecular status has to be newly defined by either resection or biopsy (54, 55).

The complication rate was low with only 0.6% permanent and 0.6% transient severe complications overall. In the subgroup of brainstem lesions, moderate or severe complications occurred at a slightly higher rate of 2.6%. Thus, even in patients with gliomas located in delicate areas such as the brainstem or the midbrain, tissue can be acquired with a low risk of permanent deficit and a high diagnostic yield. The low complication rate reported in this study justifies the application of stereotactic biopsies less reluctantly whenever diagnostic uncertainties occur during the course of disease and treatment. The low number of symptomatic hemorrhages suggests waiving the routine CT scan. Previous series of frame-based biopsies report mortality rates of 0.7–4% (28, 30–36). Post-procedural morbidity (i.e., transient or permanent neurological deficits, epileptic seizures, coma) ranged from 3 to 13%. Asymptomatic bleedings on postoperative CT scans have been reported in up to 60% of patients and symptomatic bleedings occurred in up to 8.6% of cases. In our series with no mortality, the rate of severe transient and permanent complications was much lower. In previous studies, brain biopsies typically yielded diagnoses at rates of 89–92% and even higher when intraoperative histological smears were carried out (21, 28, 31, 56–59). By comparing frame-based with frameless biopsies, no clear advantage of either technique regarding complication rates or diagnostic yield could be shown so far (29, 32, 57–60). In our experience, a high personal and interdisciplinary expertise is required to obtain

constant procedural safety and efficiency. A high caseload being taken care of by a group of few dedicated neurosurgeons is, in our opinion, important. In addition, high-resolution vascular imaging, including MR and CT angiography, meticulous planning of the trajectories by avoiding vessels, ventricular puncture, and arachnoidal contact, as the subarachnoid space is especially prone to hemorrhage, is required. Furthermore, the presence of a dedicated neuropathologist on site not only ensures specimen quality but also prevents an unnecessary high number of specimens, which is especially important in delicate locations. Also, as always in neurosurgery, proper selection of indications and patients is key. Despite low complication rates, the indication for brain biopsy must be strict as it still is an invasive procedure.

In the future, determination of changes in the molecular signature of gliomas and very early detection of therapy response or failure will gain further importance. Whether several techniques and concepts of "liquid biopsy" using CSF, plasma, or even urine may complement or even replace stereotactic biopsies for at least some indications remains yet uncertain (61–66). Also, molecular imaging using novel specific tracers might help to non-invasively better characterize gliomas in the future (67, 68).

With a mean duration of 50 min, frame-based biopsy in a streamlined setting is a time- and cost-efficient procedure. At our institution, we can perform up to five biopsies in the same OR within the regular working hours. We could obtain a high diagnostic yield with a very low rate of either inconclusive biopsies or complications. This leads to a low rate of re-biopsies, which is an important factor for both the safety and the effectiveness in the process of decision making and patient management. Hence, we consider the balance between the complexity and the costs on one side and the benefit for the patient/patient management on the other side to be in due proportion.

CONCLUSION

In conclusion, a streamlined stereotactic biopsy procedure proved to be time-effective and low-risk in primary and recurrent glioma. A high diagnostic yield enables the diagnostics of molecular markers, as required by the current WHO classification, as well as in the increasingly important context of molecular tumor boards. A postoperative CT scan should only be performed when clinically indicated. A good technical setup with easily accessible CT and a specialized team for trajectory planning and neuropathological analysis are recommended.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because of national and institutional laws to protect patient confidentiality. Requests to access the datasets should be directed to the Center for Neuropathology and Prion Research of the University Hospital of Munich.

AUTHOR CONTRIBUTIONS

JT and SQ contributed to the conception and design of the study. AD, SK, and SQ organized the database, evaluated the clinical courses, and performed the image analyses. SQ carried out the statistical analysis. SK, SQ, JW, and JT wrote the manuscript. All authors contributed to the manuscript revision, read, and approved the submitted version.

FUNDING

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2022.822362/full#supplementary-material

REFERENCES

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1

2. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol.* (2020) doi: 10.1038/s41571-020-00447-z

3. Louis D, Wiestler OD, Cavenee WK. *World Health Organization Classification of Tumours of the Central Nervous System*, 5th ed. Lyon: International Agency for Research on Cancer (2021).

4. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a society for neuro-oncology (SNO) and european society of neuro-oncology (EANO) consensus review on current management and future directions. *Neuro Oncol.* (2020) 22:1073–113. doi: 10.1093/neuonc/noaa106

5. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol.* (2021) 23:1231–51. doi: 10.1093/neuonc/noab106

6. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. *JAMA.* (2012) 308:1881–8. doi: 10.1001/jama.2012.12807

7. Southwell DG, Birk HS, Han SJ, Li J, Sall JW, Berger MS. Resection of gliomas deemed inoperable by neurosurgeons based on preoperative imaging studies. *J Neurosurg.* (2018) 129:567–75. doi: 10.3171/2017.5.JNS17166

8. Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. *JAMA Oncol.* (2020) 6:495–503. doi: 10.1001/jamaoncol.2019.6143

9. Karschnia P, Vogelbaum MA, van den Bent M, Cahill DP, Bello L, Narita Y, et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. *Eur J Cancer.* (2021) 149:23–33. doi: 10.1016/j.ejca.2021.03.002

10. Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. *J Clin Oncol.* (2017) 35:2439–49. doi: 10.1200/JCO.2017.72.7511

11. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a

report of the RANO working group. *Lancet Oncol.* (2015) 16:e534–42. doi: 10.1016/S1470-2045(15)00088-1

12. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and european association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol.* (2016) 18:1199–208. doi: 10.1093/neuonc/now058

13. Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1. 0. *Eur J Nucl Med Mol Imaging.* (2019) 46:540–57. doi: 10.1007/s00259-018-4207-9

14. Chuang MT, Liu YS, Tsai YS, Chen YC, Wang CK. Differentiating radiation-induced necrosis from recurrent brain tumor using mr perfusion and spectroscopy: a meta-analysis. *PLoS ONE.* (2016) 11:e0141438. doi: 10.1371/journal.pone.0141438

15. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. *Neuro Oncol.* (2011) 13:649–59. doi: 10.1093/neuonc/nor040

16. Lietke S, Schmutzer M, Schwartz C, Weller J, Siller S, Aumiller M, et al. Interstitial photodynamic therapy using 5-ALA for malignant glioma recurrences. *Cancers.* (2021) 13:1767. doi: 10.3390/cancers13081767

17. Weller J, Katzendobler S, Karschnia P, Lietke S, Egensperger R, Thon N, et al. PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. *J Neurooncol.* (2021) 153:283–91. doi: 10.1007/s11060-021-03765-z

18. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. *Cell.* (2013) 155:462–77. doi: 10.1016/j.cell.2013.09.034

19. Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. *Ann Oncol.* (2017) 28:1457–72. doi: 10.1093/annonc/mdx106

20. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature.* (2020) 580:517–23. doi: 10.1038/s41586-020-2209-9

21. Dhawan S, Venteicher AS, Butler WE, Carter BS, Chen CC. Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis. *J Neurooncol.* (2021) 154:1–11. doi: 10.1007/s11060-021-03785-9

22. US Department of Health and Human Services; National Institutes of Health NCI. *Common Terminology Criteria for Adverse Events (CTCAE) Version 5.* Washington, DC: U.S. Department of Health and Human Services (2017).

23. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. *Int J Cancer.* (2005) 113:379–85. doi: 10.1002/ijc.20575

24. Suchorska B, Schuller U, Biczok A, Lenski M, Albert NL, Giese A, et al. Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. *Eur J Cancer.* (2019) 107:15–27. doi: 10.1016/j.ejca.2018.10.019

25. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathol.* (2013) 126:917–29. doi: 10.1007/s00401-013-1198-2

26. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. *Int J Cancer.* (2007) 121:2458–64. doi: 10.1002/ijc.23020

27. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. *Nature.* (2018) 555:469–74. doi: 10.1038/nature26000

28. Riche M, Amelot A, Peyre M, Capelle L, Carpentier A, Mathon B. Complications after frame-based stereotactic brain biopsy: a systematic review. *Neurosurg Rev.* (2021) 44:301–7. doi: 10.1007/s10143-019-01234-w

29. Hall WA. The safety and efficacy of stereotactic biopsy for intracranial lesions. *Cancer.* (1998) 82:1749–55. doi: 10.1002/(sici)1097-0142(19980501)82:9<1756::aid-cncr23>3.0.co;2-2

30. Kongkham PN, Knifed E, Tamber MS, Bernstein M. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing procedure. *Can J Neurol Sci.* (2008) 35:79–84. doi: 10.1017/S0317167100007605

31. Ferreira MP, Ferreira NP, Pereira Filho Ade A, Pereira Filho Gde A, Franciscatto AC. Stereotactic computed tomography-guided brain biopsy: diagnostic yield based on a series of 170 patients. *Surg Neurol.* (2006) 65(Suppl. 1):S1:27–1.32. doi: 10.1016/j.surneu.2005.11.036

32. Dammers R, Haitsma IK, Schouten JW, Kros JM, Avezaat CJ, Vincent AJ. Safety and efficacy of frameless and frame-based intracranial biopsy techniques. *Acta Neurochir.* (2008) 150:23–9. doi: 10.1007/s00701-007-1473-x

33. Chen CC, Hsu PW, Erich Wu TW, Lee ST, Chang CN, Wei KC, et al. Stereotactic brain biopsy: single center retrospective analysis of complications. *Clin Neurol Neurosurg.* (2009) 111:835–9. doi: 10.1016/j.clineuro.2009.08.013

34. Burns JD, Cadigan RO, Russell JA. Evaluation of brain biopsy in the diagnosis of severe neurologic disease of unknown etiology. *Clin Neurol Neurosurg.* (2009) 111:235–9. doi: 10.1016/j.clineuro.2008.10.003

35. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. *J Neurosurg.* (1994) 81:165–8. doi: 10.3171/jns.1994.81.2.0165

36. Bai HX, Zou Y, Lee AM, Lancaster E, Yang L. Diagnostic value and safety of brain biopsy in patients with cryptogenic neurological disease: a systematic review and meta-analysis of 831 cases. *Neurosurgery.* (2015) 77:283–95; discussion 95. doi: 10.1227/NEU.0000000000000756

37. Galldiks N, Lohmann P, Werner JM, Ceccon G, Fink GR, Langen KJ. Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. *Expert Rev Anticancer Ther.* (2020) 20:9–15. doi: 10.1080/14737140.2020.1705788

38. Chen LH, Pan C, Diplas BH, Xu C, Hansen LJ, Wu Y, et al. The integrated genomic and epigenomic landscape of brainstem glioma. *Nat Commun.* (2020) 11:3077. doi: 10.1038/s41467-020-16682-y

39. Hoffman LM, DeWire M, Ryall S, Buczkowicz P, Leach J, Miles L, et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. *Acta Neuropathol Commun.* (2016) 4:1. doi: 10.1186/s40478-015-0269-0

40. Eigenbrod S, Trabold R, Brucker D, Eros C, Egensperger R, La Fougere C, et al. Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. *Acta Neurochir.* (2014) 156:1427–40. doi: 10.1007/s00701-014-2073-1

41. Thon N, Tonn JC, Kreth FW. The surgical perspective in precision treatment of diffuse gliomas. *Onco Targets Ther.* (2019) 12:1497–508. doi: 10.2147/OTT.S174316

42. Kunz M, Albert NL, Unterrainer M, la Fougere C, Egensperger R, Schuller U, et al. Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. *Neuro Oncol.* (2019) 21:274–84. doi: 10.1093/neuonc/noy098

43. Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, et al. Hot spots in dynamic FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. *Neuro Oncol.* (2011) 13:307–16. doi: 10.1093/neuonc/noq196

44. Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. *J Neuropathol Exp Neurol.* (2009) 68:1219–28. doi: 10.1097/NEN.0b013e3181bee1f1

45. Korber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, et al. Evolutionary trajectories of IDH(WT) glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. *Cancer Cell.* (2019) 35:692–704 e12. doi: 10.1016/j.ccell.2019.02.007

46. Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. *Nat Commun.* (2018) 9:2087. doi: 10.1038/s41467-018-04448-6

47. van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. *Acta Neuropathol.* (2015) 129:597–607. doi: 10.1007/s00401-015-1403-6

48. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science.* (2014) 343:189–93. doi: 10.1126/science.1239947

49. Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. *Neuro Oncol.* (2021) 23:1872–84. doi: 10.1093/neuonc/noab081

50. Pham TV, Goodman AM, Sivakumar S, Frampton G, Kurzrock R. Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers. *Genome Med.* (2021) 13:159. doi: 10.1186/s13073-021-00979-8

51. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. *Int J Cancer.* (2011) 129:659–70. doi: 10.1002/ijc.26083

52. van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van Zwieten K, et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. *Neuro Oncol.* (2015) 17:935–41. doi: 10.1093/neuonc/nov013

53. Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. *Clin Cancer Res.* (2017) 23:6846–55. doi: 10.1158/1078-0432.CCR-17-0890

54. French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, et al. Defining EGFR amplification status for clinical trial inclusion. *Neuro Oncol.* (2019) 21:1263–72. doi: 10.1093/neuonc/noz096

55. Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, et al. Molecular evolution of IDH wild-type glioblastomas treated with standard of care affects survival and design of precision medicine trials: a report from the EORTC 1542 study. *J Clin Oncol.* (2020) 38:81–99. doi: 10.1200/JCO.19.00367

56. Mathon B, Amelot A, Mokhtari K, Bielle F. Increasing the diagnostic yield of stereotactic brain biopsy using intraoperative histological smear. *Clin Neurol Neurosurg.* (2019) 186:105544. doi: 10.1016/j.clineuro.2019.105544

57. Woodworth GF, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD. Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique. *J Neurosurg.* (2006) 104:233–7. doi: 10.3171/jns.2006.104.2.233

58. Bekelis K, Radwan TA, Desai A, Roberts DW. Frameless robotically targeted stereotactic brain biopsy: feasibility, diagnostic yield, and safety. *J Neurosurg.* (2012) 116:1002–6. doi: 10.3171/2012.1.JNS111746

59. Barnett GH, Miller DW, Weisenberger J. Frameless stereotaxy with scalp-applied fiducial markers for brain biopsy procedures: experience in 218 cases. *J Neurosurg.* (1999) 91:569–76. doi: 10.3171/jns.1999.91.4.0569

60. Lu Y, Yeung C, Radmanesh A, Wiemann R, Black PM, Golby AJ. Comparative effectiveness of frame-based, frameless, and intraoperative magnetic resonance imaging-guided brain biopsy techniques. *World Neurosurg.* (2015) 83:261–8. doi: 10.1016/j.wneu.2014.07.043

61. Gatto L, Franceschi E, Di Nunno V, Tosoni A, Lodi R, Brandes AA. Liquid biopsy in glioblastoma management: from current research to future perspectives. *Oncologist.* (2021) 26:865–78. doi: 10.1002/onco.13858

62. Mouliere F, Smith CG, Heider K, Su J, van der Pol Y, Thompson M, et al. Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. *EMBO Mol Med.* (2021) 13:e12881. doi: 10.15252/emmm.202012881

63. Billard P, Guerriau C, Carpentier C, Juillard F, Grandin N, Lomonte P, et al. The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches. *Ann Oncol.* (2021). doi: 10.1016/j.annonc.2021.09.004

64. Mathios D, Phallen J. Circulating biomarkers in glioblastoma: ready for prime time? *Cancer J.* (2021) 27:404–9. doi: 10.1097/PPO.0000000000000541

65. On J, Natsumeda M, Watanabe J, Saito S, Kanemaru Y, Abe H, et al. Low detection rate of h3k27m mutations in cerebrospinal fluid obtained from lumbar puncture in newly diagnosed diffuse midline gliomas. *Diagnostics.* (2021) 11:681. doi: 10.3390/diagnostics11040681

66. Kang KM, Muralidharan K, Yekula A, Small JL, Rosh ZS, Jones PS, et al. Blood-based detection of BRAF V600E in gliomas and brain tumor metastasis. *Cancers.* (2021) 13:1227. doi: 10.3390/cancers13061227

67. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, et al. Imaging of integrin alpha(v)beta expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. *Neuro Oncol.* (2009) 11:861–70. doi: 10.1215/15228517-2009-024

68. Unterrainer M, Fleischmann DF, Vettermann F, Ruf V, Kaiser L, Nelwan D, et al. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative F-GE-180 PET study. *Eur J Nucl Med Mol Imaging.* (2020) 47:1368–80. doi: 10.1007/s00259-019-04491-5